MAPT and Alzheimer disease: It is generally recognized that CSF t-tau is a biomarker for the intensity of neurodegeneration (Blennow and Zetterberg, 2018), and Aβ is the upstream of tau in the pathogenesis of AD by triggering tau from the normal state to toxic state (Bloom, 2014; Buckley et al., 2019).